Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,456 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,550 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02685267 | Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer(Doce/Enza) | terminated | Phase 2 | 9 | Prostate Cancer Clinical Trials ConsortiumOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT00991315 | Collecting and Storing Blood and Tumor Tissue Samples From Patients Undergoing Prostatectomy or Transurethral Resection of the Prostate | terminated | — | 126 | Rutgers, The State University of New JerseyOTHER |
| 1 |
| Apr 8, 2021 |
| clinicaltrials |
| NCT02853097 | Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients | terminated | — | 7 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT01376661 | Outcome Assessment of an Active Surveillance Program for Low Risk Prostate Cancer: An Observational Study | terminated | — | 8 | St. Joseph Hospital of OrangeOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03042312 | Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy(RESIST-PC) | terminated | Phase 2 | 71 | EndocyteINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT04305379 | Augmented BLAdder NecK rEconstruction Trial for Improved Urinary Function After Radical Prostatectomy(BLANKET) | terminated | N/A | 31 | Johns Hopkins UniversityOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03572478 | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | terminated | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT01717677 | Evaluation of Four Treatment Modalities in Prostate Cancer With Low or "Early Intermediate" Risk(PREFERE) | terminated | N/A | 457 | Association of Urologic Oncology (AUO)OTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT03261336 | Oral Calcitriol With Ketoconazole in CRPC | terminated | Phase 2 | 1 | Donald Trump, MDOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | terminated | Phase 1 / Phase 2 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | SOTIO a.s.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 2 | University of California, DavisOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03327662 | Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer(CTC-STOP) | terminated | Phase 3 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT00757757 | A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases | terminated | Phase 1 / Phase 2 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT00058188 | Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation | terminated | Phase 3 | 53 | Northwestern UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT00780975 | A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer | terminated | Phase 2 | 8 | PharmaMarINDUSTRY | 1 | Nov 24, 2020 | clinicaltrials |
| NCT04266262 | High-Intensity Training for Men With Prostate Cancer on Active Surveillance: A Feasibility Study | terminated | N/A | 25 | University of TorontoOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT01928485 | Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer | terminated | Phase 2 | 6 | Sanjay Gupta PhDOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02006927 | A Pilot Study of the Feasibility of Chronic Cavernous Nerve Stimulation to Promote Regeneration and Erectile Function | terminated | N/A | 3 | Kenneth M Peters, MDOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00004026 | CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy | terminated | Phase 2 | 80 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Sep 21, 2020 | clinicaltrials |
| NCT01414712 | Circulating Tumor Cells in Prostate Cancer Patients | terminated | — | 2 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT03006562 | PREvention of VENous ThromboEmbolism Following Radical Prostatectomy(PREVENTER) | terminated | Phase 4 | 501 | Johns Hopkins UniversityOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT02911467 | Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer(MR) | terminated | Phase 1 | 8 | Rahul AggarwalOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer | terminated | Phase 2 | 57 | University of California, San FranciscoOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT03827473 | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer(ACADEMIC) | terminated | Phase 2 | 1 | University of UtahOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT01545882 | A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer(OTT10-06) | terminated | Phase 2 | 5 | Ottawa Hospital Research InstituteOTHER | 1 | May 7, 2020 | clinicaltrials |
| NCT00003645 | Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence | terminated | Phase 3 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT03093272 | A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer | terminated | Phase 2 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT03634579 | MRI Guided Prostate Cancer Focal Laser Ablation | terminated | N/A | 9 | Emory UniversityOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT03763851 | Cannabis Oil and Radiation Therapy for the Management of Pain | terminated | Phase 2 | 100 | Tetra Bio-PharmaINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT03137758 | A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 | 12 | Pellficure Pharmaceuticals, IncINDUSTRY | 1 | Mar 9, 2020 | clinicaltrials |
| NCT01499043 | Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC) | terminated | Phase 2 | 6 | Daiichi SankyoINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
| NCT03043989 | Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin | terminated | Phase 1 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00464724 | 3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate | terminated | N/A | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT03256630 | Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer | terminated | — | 128 | Genomic Health®, Inc.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02311764 | Carboplatin in Castration-resistant Prostate Cancer(PRO-PLAT) | terminated | Phase 2 | 16 | Aurelius OmlinOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT02809846 | Quell Opioid Reduction and Pain Relief in Patients With Cancer | terminated | N/A | 33 | Scripps Translational Science InstituteOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT02771769 | Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels | terminated | — | 500 | Chronix Biomedical CorporationINDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT00937768 | Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy | terminated | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00582582 | Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer | terminated | Phase 2 | 70 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00585117 | Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients | terminated | N/A | 9 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | terminated | Phase 2 / Phase 3 | 16 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01816048 | NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis | terminated | Phase 2 | 8 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00415246 | Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer | terminated | Phase 3 | 100 | IpsenINDUSTRY | 8 | Nov 22, 2019 | clinicaltrials |
| NCT01313273 | Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients(POSEIDON) | terminated | Phase 3 | 3 | IpsenINDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT00702923 | CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer | terminated | Phase 1 | 12 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Apr 9, 2021source: clinicaltrials